Dr Kellie Charles
|
D06 - Blackburn Building
The University of Sydney NSW 2006 Australia |
Dr Charles' research aims to investigate the interactions between malignant cells and immune cells that regulate tumour progression. Tumour-associated macrophages are one of the main immune cells in cancer that support tumour growth and metastasis in most human cancers. Malignant cells secrete cytokines and chemokines that alter the phenotype and behaviour of tumour-associated macrophages to promote tumour growth and orchestrate the immunosuppressant behaviour of the adaptive immune responses. Inhibiting the communication between cancer cells and tumour-associated macrophages is becoming an exciting potential target for cancer intervention strategies. Dr Charles conducts translational and clinical studies aimed to identify new molecular targets in cancer and in collaboration with biological chemists at the University of Sydney design and evaluate new cancer therapeutic agents.
2009
- Chua, W, Moore, M, Charles, K, Clarke, S. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics. 2009; 11:611-622
- Charles, K, Kulbe, H, Soper, R, Escorcio-Correia, M, Lawrence, T, Schultheis, A, Chakravarty, P, Thompson, R, Kollias, G, Smyth, J, Balkwill, F, Hagemann, T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation. 2009; 119:3011-3023
2008
- Brown, E, Charles, K, Hoare, S, Rye, R, Jodrell, D, Aird, R, Vora, R, Prabhakar, U, Nakada, M, Corringham, R, DeWitte, M, Sturgeon, C, Propper, D, Balkwill, F, Smyth, J. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Annals of Oncology. 2008; 19:1340-1346
- Hagemann, T, Lawrence, T, McNeish, I, Charles, K, Kulbe, H, Thompson, R, Robinson, S, Balkwill, F. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. The Journal of Experimental Medicine. 2008; 205:1261-1268
- Morgan, E, Goralski, K, Piquette-Miller, M, Renton, K, Robertson, G, Chaluvadi, M, Charles, K, Clarke, S, Kacevska, M, Liddle, C, Richardson, T, Sharma, R, Sinal, C. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metabolism and Disposition. 2008; 36:205-216
2007
- Harrison, M, Obermueller, E, Maisey, N, Hoare, S, Edmonds, K, Li, N, Chao, D, Hall, K, Lee, C, Timotheadou, E, Charles, K, Ahern, R, King, D, Eisen, T, Corringham, R, DeWitte, M, Balkwill, F, Gore, M. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. Journal of clinical oncology. 2007; 25:4542-4549
- Hagemann, T, Robinson, S, Thompson, R, Charles, K, Kulbe, H, Balkwill, F. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular cancer therapeutics. 2007; 6:1993-2002
2006
- Charles, K, Rivory, L, Brown, S, Liddle, C, Clarke, S, Robertson, G. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12:7492-7
- Hagemann, T, Wilson, J, Burke, F, Kulbe, H, Li, N, Plüddemann, A, Charles, K, Gordon, S, Balkwill, F. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Journal of immunology. 2006; 176:5023-5032
- Szlosarek, P, Charles, K, Balkwill, F. Tumour necrosis factor-alpha as a tumour promoter. European journal of cancer. 2006; 42:745-750
- Charles, K, Rivory, L, Stockler, M, Beale, P, Beith, J, Boyer, M, Clarke, S. Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical pharmacokinetics. 2006; 45:611-22
2005
- Hagemann, T, Wilson, J, Kulbe, H, Li, N, Leinster, D, Charles, K, Klemm, F, Pukrop, T, Binder, C, Balkwill, F. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. Journal of immunology. 2005; 175:1197-1205
- Balkwill, F, Charles, K, Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell. 2005; 7:211-217
2004
- Baker, S, van Schaik, R, Rivory, L, Ten Tije, A, Dinh, K, Graveland, W, Schenk, P, Charles, K, Clarke, S, Carducci, M, McGuire, W, Dawkins, F, Gelderblom, H, Verweij, J, Sparreboom, A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10:8341-50
- Slaviero, K, Clarke, S, McLachlan, A, Blair, E, Rivory, L. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. British journal of clinical pharmacology. 2004; 57:44-53
2003
- Slaviero, K, Clarke, S, Rivory, L. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. The lancet oncology. 2003; 4:224-232
- Slaviero, K, Read, J, Clarke, S, Rivory, L. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutrition and cancer. 2003; 46:148-157
2002
- Rivory, L, Slaviero, K, Clarke, S. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British journal of cancer. 2002; 87:277-280
